A5056387366- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Genetic Neurodegenerative Diseases
- Neurological and metabolic disorders
- Glycogen Storage Diseases and Myoclonus
- Neurological diseases and metabolism
- Restless Legs Syndrome Research
- Epilepsy research and treatment
- Mitochondrial Function and Pathology
- Peripheral Neuropathies and Disorders
- Metabolism and Genetic Disorders
- Autoimmune Neurological Disorders and Treatments
- Parkinson's Disease and Spinal Disorders
- Sleep and Wakefulness Research
- Pharmacological Effects and Toxicity Studies
- Cerebral Palsy and Movement Disorders
- Prostate Cancer Diagnosis and Treatment
- Hereditary Neurological Disorders
- Neurology and Historical Studies
- Urinary Bladder and Prostate Research
- Organ Transplantation Techniques and Outcomes
- Cancer Treatment and Pharmacology
- Autism Spectrum Disorder Research
- Cardiovascular Syncope and Autonomic Disorders
Augusta University
2015-2025
The University of Melbourne
2008-2025
St Vincent's Hospital
2022-2025
Austin Health
2011-2025
St Vincent's Health
2024
Jaipur Golden Hospital
2024
Footscray Hospital
2022
Western Health
2022
Parkinson's Foundation
2007-2021
Foundation Center
2006-2021
Abstract Nonmotor symptoms (NMS) of Parkinson's disease (PD) are not well recognized in clinical practice, either primary or secondary care, and frequently missed during routine consultations. There is no single instrument (questionnaire scale) that enables a comprehensive assessment the range NMS PD both for identification problems measurement outcome. Against this background, multidisciplinary group experts, including patient representatives, has developed an screening questionnaire...
Abstract Non‐motor symptoms (NMS) in Parkinson's disease (PD) are common, significantly reduce quality of life and at present there is no validated clinical tool to assess the progress or potential response treatment NMS. A new 30‐item scale for assessment NMS PD (NMSS) was developed. NMSS contains nine dimensions: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, miscellany. The metric attributes this instrument...
As there are no biological markers for the antemortem diagnosis of degenerative parkinsonian disorders, currently relies upon presence and progression clinical features confirmation depends on neuropathology. Clinicopathologic studies have shown significant false-positive false-negative rates diagnosing these misdiagnosis is especially common during early stages diseases. It important to establish a set widely accepted diagnostic criteria disorders that may be applied reproduced in blinded...
Abstract 2006, there was, no single instrument (questionnaire or scale) for attempting a comprehensive assessment of the wide range nonmotor symptoms (NMS) Parkinson's disease (PD). The PD group, multidisciplinary group experts including patient representatives developed and validated NMS screening questionnaire (NMSQuest) comprising 30 items. NMSQuest is self completed tool designed to draw attention presence NMS. In this paper, we present results gathered from 545 patients using definitive...
The nonmotor symptoms (NMS) of Parkinson's disease (PD) are less well recognised and can be more troublesome to patients carers than classical motor features. NMS frequently missed during routine consultations such under-recognition may have implications on quality care given that many treatable. To determine the proportion not declaring healthcare professional (HCP) as assessed by self completion questionnaire (NMSQuest), a validated, self-completing with 30 items. Multicentre international...
<h3>Importance</h3> Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons, and was safe well tolerated early-phase human studies. A previous phase II study suggested possible clinical benefit. <h3>Objective</h3> To examine whether CoQ10 could slow progression early PD. <h3>Design, Setting, Participants</h3> III randomized, placebo-controlled, double-blind trial at 67 North...
A prospective, randomized, placebo-controlled, double-blind, parallel-group, 6-month study assessed the efficacy and safety of ropinirole, a nonergoline D2-dopamine agonist, in patients with early Parkinson's disease (n = 241; Hoehn & Yahr stages I to III) limited or no prior dopaminergic therapy. Patients (mean age, 62.8 years), stratified by concomitant use selegiline, were randomized ropinirole (n= 116) placebo 125). The starting dose was 0.25 mg tid titration at least 1.5 (maximum dose,...
<b>Background:</b> Nonmotor symptoms (NMS) have a great impact on patients with Parkinson disease (PD). The Non-Motor Symptoms Scale (NMSS) is an instrument specifically designed for the comprehensive assessment of NMS in PD. NMSS psychometric properties been tested this study. <b>Methods:</b> Data were collected 12 centers across 10 countries America, Asia, and Europe. In addition to NMSS, following measures applied: Scales Outcomes Parkinson's Disease (SCOPA)-Motor, SCOPA-Psychiatric...
Abstract This study compares the sensitivity of a Patient Questionnaire versus information gathered by clinicians at routine clinic visit in recognizing symptoms wearing‐off early Parkinson's disease (PD). Questionnaire, containing 32 items representing wide spectrum motor and nonmotor symptoms, was administered to subjects attending two PD clinics. The results were compared clinician from Unified Disease Rating Scale (UPDRS) Part IV, Question 36 specific Clinical Assessment regarding loss...
Restless legs syndrome (RLS) is a neurological condition with significant impact on sleep and quality of life (QoL). This double-blind, randomized, 12-week, multinational study compared the efficacy safety ropinirole placebo in RLS. In total, 267 outpatients moderate-to-severe RLS were randomly assigned to (0.25-4.0 mg/day) or placebo, 1 3 hours before bedtime. The primary endpoint was change International Legs Scale (IRLS) score at week 12. Key secondary endpoints percentage patients...
To evaluate the safety and efficacy of botulinum toxin type A injection in essential tremor hand.Botulinum is an effective treatment for dystonia, spasticity, other movement disorders has been found to be useful open-label studies one double-masked study hand tremor.One hundred thirty-three patients with were randomized low-dose (50 U) or high-dose (100 (Botox) vehicle placebo treatment. Injections made into wrist flexors extensors. Patients followed 16 weeks. The effect was assessed by...
<b>Objective: </b> To evaluate the nonergot dopamine agonist ropinirole as an adjunct to L-dopa in a randomized, double-blind trial PD patients with motor fluctuations. <b>Background: treatment of is associated fluctuations, dyskinesia, and other adverse effects. The use agonists delays recourse thus possibility effect onset. <b>Methods: Ropinirole (n = 95) or placebo 54) was added L-dopa, then reduced planned manner during 6-month trial. <b>Results: A significantly greater number were able...
Abstract Background: The objective of this study was to determine the reliability a new scale for clinical assessment essential tremor. Essential Tremor Rating Assessment Scale contains 9 performance items that rate action tremor in head, face, voice, limbs, and trunk from 0 4 half‐point intervals. Head limb ratings are defined by specific amplitude ranges centimeters. Methods: Videos 44 patients 6 controls were rated 10 specialists on 2 occasions 1–2 months apart. Inter‐ intrarater assessed...
Abstract Two women with a presumptive diagnosis of Hallervor‐den‐Spatz syndrome had combination dystonia and parkinsonism. One retinitis pigmentosa. Neuropsychological testing revealed Decemberreased verbal fluency visuoconstructional motor deficits. Magnetic resonance imaging performed high‐field‐strength unit (1.5 Tesla) showed striking abnormalities in the globus pallidus bilaterally (“eye‐of‐the‐tiger” sign). may prove useful Hallervorden‐Spatz syndrome.
To evaluate the efficacy and safety of pramipexole in patients with moderate to severe restless legs syndrome (RLS) METHODS: The authors conducted a 12-week, double-blind, randomized, placebo-controlled trial fixed doses (0.25, 0.50, 0.75 mg/day). Patients (N = 344) were up-titrated their randomized dose over 3 weeks. primary endpoints patient ratings symptom severity on International RLS Study Group Rating Scale (IRLS) clinician improvement Clinical Global Impressions-Improvement (CGI-I)...
Abstract To test the association between impaired olfaction and other prodromal features of PD in Parkinson At‐Risk Syndrome Study. The onset olfactory dysfunction typically precedes motor features, suggesting that testing could be used as a screening test. A combined strategy uses nonmotor along with testing, may more efficient than hyposmia alone for detecting risk PD. Individuals no neurological diagnosis completed mail survey, including 40‐item University Pennsylvania Smell...
We tested the feasibility of a computer based at-home testing device (AHTD) in early-stage, unmedicated Parkinson's disease (PD) patients over 6 months. measured compliance, technical reliability, and patient satisfaction to weekly assessments tremor, small large muscle bradykinesia, speech, reaction/movement times, complex motor control. relative UPDRS score. The AHTD is 6.5'' x 10'' computerized assessment battery. Data are stored on USB memory stick sent by internet central data...
Abstract ADS‐5102 is a long‐acting, extended‐release capsule formulation of amantadine HCl administered once daily at bedtime. This study investigated the safety, efficacy, and tolerability in Parkinson's disease (PD) patients with levodopa‐induced dyskinesia. was randomized, double‐blind, placebo‐controlled, parallel‐group 83 PD troublesome dyskinesia assigned to placebo or one three doses (260 mg, 340 420 mg) bedtime for 8 weeks. The primary efficacy analysis compared change from baseline...